Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

PaTH Forward: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of TransCon PTH in Adult Hypoparathyroidism

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Dynamic changes of reproductive hormones in male minipuberty: Temporal dissociation of Leydig- and Sertoli-cell activity

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Patients with cirrhosis have elevated bone turnover but normal hepatic production of osteoprotegerin

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Lipoprotein(a) levels at birth and in early childhood: The COMPARE Study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Entero-pancreatic hormone secretion, gastric emptying, and glucose absorption after frequently sampled meal tests

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. Vitamin D supplementation improves fasting insulin levels and HDL cholesterol in infertile men

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Denosumab vs. zoledronic acid treatment in post-menopausal breast cancer: a 2-year prospective observational study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Concomitant familial hypocalciuric hypercalcemia and single parathyroid adenoma: a case report

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Anxiety Levels Predict Bone Mineral Density in Postmenopausal Women Undergoing Oral Bisphosphonates: A Two-Year Follow-Up

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Aliya A Khan
  • Lars Rejnmark
  • Mishaela Rubin
  • Peter Schwarz
  • Tamara Vokes
  • Bart Clarke
  • Intekhab Ahmed
  • Lorenz Hofbauer
  • Claudio Marcocci
  • Uberto Pagotto
  • Andrea Palermo
  • Erik Eriksen
  • Meryl Brod
  • Denka Markova
  • Alden Smith
  • Susanne Pihl
  • Sanchita Mourya
  • David B Karpf
  • Aimee D Shu
Vis graf over relationer

CONTEXT: Hypoparathyroidism is characterized by insufficient levels of parathyroid hormone (PTH). TransCon PTH is an investigational long-acting prodrug of PTH(1-34) for the treatment of hypoparathyroidism.

OBJECTIVE: This work aimed to investigate the safety, tolerability, and efficacy of daily TransCon PTH in adults with hypoparathyroidism.

METHODS: This phase 2, randomized, double-blind, placebo-controlled 4-week trial with open-label extension enrolled 59 individuals with hypoparathyroidism. Interventions included TransCon PTH 15, 18, or 21 µg PTH(1-34)/day or placebo for 4 weeks, followed by a 22-week extension during which TransCon PTH dose was titrated (6-60 µg PTH[1-34]/day).

RESULTS: By Week 26, 91% of participants treated with TransCon PTH achieved independence from standard of care (SoC, defined as active vitamin D = 0 μg/day and calcium [Ca] ≤ 500 mg/day). Mean 24-hour urine Ca (uCa) decreased from a baseline mean of 415 mg/24h to 178 mg/24h by Week 26 (n = 44) while normal serum Ca (sCa) was maintained and serum phosphate and serum calcium-phosphate product fell within the normal range. By Week 26, mean scores on the generic 36-Item Short Form Health Survey domains increased from below normal at baseline to within the normal range. The Hypoparathyroidism Patient Experience Scale symptom and impact scores improved through 26 weeks. TransCon PTH was well tolerated with no treatment-related serious or severe adverse events.

CONCLUSION: TransCon PTH enabled independence from oral active vitamin D and reduced Ca supplements (≤ 500 mg/day) for most participants, achieving normal sCa, serum phosphate, uCa, serum calcium-phosphate product, and demonstrating improved health-related quality of life. These results support TransCon PTH as a potential hormone replacement therapy for adults with hypoparathyroidism.

OriginalsprogEngelsk
TidsskriftThe Journal of clinical endocrinology and metabolism
Vol/bind107
Udgave nummer1
Sider (fra-til)e372-e385
ISSN0021-972X
DOI
StatusUdgivet - 1 jan. 2022

Bibliografisk note

© The Author(s) 2021. Published by Oxford University Press on behalf of the Endocrine Society.

ID: 74470439